Daratumumab for pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report
10.13303/j.cjbt.issn.1004-549x.2025.12.017
- VernacularTitle:达雷妥尤治疗异基因造血干细胞移植后纯红细胞再生障碍性贫血一例
- Author:
Li ZHANG
1
;
Yu QI
1
;
Guangcui HE
2
;
Tao PENG
1
;
Xinyu GAN
1
;
Hai YI
2
Author Information
1. Department of Blood Transfusion, The General Hospital of Western Theater Command, Chengdu 610083, China
2. Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, China
- Publication Type:Journal Article
- Keywords:
allogeneic hematopoietic stem cell transplantation (allo-HSCT);
pure red cell aplasia (PRCA);
daratumumab;
antibody titer
- From:
Chinese Journal of Blood Transfusion
2025;38(12):1759-1763
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To summarize the treatment methods and efficacy of a patient with pure red cell aplasia (PRCA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to accumulate relevant case data. Methods: The clinical treatment and laboratory test data of a patient with PRCA after allo-HSCT in our hospital were retrospectively collected. The therapeutic strategy, monitoring parameters, and treatment outcomes were summarized. Results: Upon suspicion of post-transplant PRCA, the patient was promptly treated with intravenous injection of human immunoglobulin and three sessions of plasma exchange. The titer of blood group antibodies in the patient decreased, and the hemolytic symptoms were relieved. Over one year post-transplantation, the patient exhibited a sustained impairment of erythropoiesis, necessitating continued red blood cell transfusions. After treatment with intravenous daratumumab (400 mg twice weekly for 4 weeks), the pateint's hemoglobin (Hb) and reticulocyte (Ret) levels normalized rapidly, the ABO blood type converted from the recipient to the donor type, and the titer of IgM blood group antibodies returned to normal. The patient was successfully weaned off red blood cell transfusions, indicating the clinical efficacy of the treatment. Conclusion: Daratumumab shows effectiveness in the treatment of refractory PRCA after allo-HSCT in the case. It is essential to monitor Hb, Ret and the titer of blood group antibodies during treatment. Nevertheless, the interference of daratumumab with the titer of blood group antibodies should be considered.
